- Effects of Rosiglitazone on Inflammation in Otsuka Long-Evans Tokushima Fatty Rats
-
Jin Woo Lee, Il Seong Nam-Goong, Jae Geun Kim, Chang Ho Yun, Se Jin Kim, Jung Il Choi, Young IL Kim, Eun Sook Kim
-
Korean Diabetes J. 2010;34(3):191-199. Published online June 30, 2010
-
DOI: https://doi.org/10.4093/kdj.2010.34.3.191
-
-
4,945
View
-
26
Download
-
7
Crossref
-
 Abstract
 PDF PubReader
- Background
Inflammation plays a role in the response to metabolic stress in type 2 diabetes. However, the effects of rosiglitazone on inflammation of skeletal muscle have not been fully examined in type 2 diabetes. MethodsWe investigated the effects of the insulin-sensitizing anti-diabetic agent, rosiglitazone, on the progression of skeletal muscle inflammation in Otsuka Long-Evans Tokushima Fatty (OLETF) type 2 diabetic rats. We examined the expression of serologic markers (serum glucose, insulin and free fatty acid) and inflammatory cytokines (tumor-necrosis factor-α, interleukin [IL]-1β and IL-6) in OLETF rats from early to advanced diabetic stage (from 28 to 40 weeks of age). ResultsSerum glucose and insulin concentrations were significantly decreased in rosiglitazone-treated OLETF rats compared to untreated OLETF rats. Rosiglitazone treatment significantly decreased the concentrations of serum inflammatory cytokines from 28 to 40 weeks of age. The mRNA expression of various cytokines in skeletal muscle was reduced in rosiglitazone-treated OLETF rats compared with untreated OLETF rats. Furthermore, rosiglitazone treatment resulted in the downregulation of ERK1/2 phosphorylation and NF-κB expression in the skeletal muscle of OLETF rats. ConclusionThese results suggest that rosiglitazone may improve insulin sensitivity with its anti-inflammatory effects on skeletal muscle.
-
Citations
Citations to this article as recorded by  - Rosiglitazone Elicits an Adiponectin-Mediated Insulin-Sensitizing Action at the Adipose Tissue-Liver Axis in Otsuka Long-Evans Tokushima Fatty Rats
Jia Li, Yao-Ming Xue, Bo Zhu, Yong-Hua Pan, Yan Zhang, Chunxia Wang, Yuhao Li
Journal of Diabetes Research.2018; 2018: 1. CrossRef - Sirt1 and Sirt6 Mediate Beneficial Effects of Rosiglitazone on Hepatic Lipid Accumulation
Soo Jin Yang, Jung Mook Choi, Eugene Chang, Sung Woo Park, Cheol-Young Park, Aimin Xu
PLoS ONE.2014; 9(8): e105456. CrossRef - Beneficial effects of co-enzyme Q10 and rosiglitazone in fructose-induced metabolic syndrome in rats
Suzan M. Mansour, Hala F. Zaki, Ezz-El-Din S. El-Denshary
Bulletin of Faculty of Pharmacy, Cairo University.2013; 51(1): 13. CrossRef - Chromium Picolinate and Rosiglitazone Improve Biochemical Derangement in a Rat Model of Insulin Resistance: Role of TNF-a and Leptin
Suzan M. Mansour, Hala F. Zaki, Ezz-El-Din El-Denshar
Pharmacologia.2013; 4(3): 186. CrossRef - Angiotensin Receptor Blockade Increases Pancreatic Insulin Secretion and Decreases Glucose Intolerance during Glucose Supplementation in a Model of Metabolic Syndrome
Ruben Rodriguez, Jose A. Viscarra, Jacqueline N. Minas, Daisuke Nakano, Akira Nishiyama, Rudy M. Ortiz
Endocrinology.2012; 153(4): 1684. CrossRef - Rodent Models for Metabolic Syndrome Research
Sunil K. Panchal, Lindsay Brown, Andrea Vecchione
BioMed Research International.2011;[Epub] CrossRef - Letter: Effects of Rosiglitazone on Inflammation in Otsuka Long-Evans Tokushima Fatty Rats (Korean Diabetes J 2010;34:191-9)
Soo Jin Yang, Cheol-Young Park
Korean Diabetes Journal.2010; 34(4): 261. CrossRef
|
KDA
